Literature DB >> 27255662

Impact of Body Mass Index on the Prognosis of Japanese Patients With Non-Valvular Atrial Fibrillation.

Hiroshi Inoue1, Eitaro Kodani2, Hirotsugu Atarashi2, Ken Okumura3, Takeshi Yamashita4, Hideki Origasa5.   

Abstract

Obesity is a risk factor for atrial fibrillation (AF); however, obesity is associated with lower mortality in patients with established AF, a phenomenon known as the obesity paradox. Previous studies reported inconsistent results regarding effects of body weight on risk of cardiogenic embolism in patients with AF. To determine relation between body mass index (BMI) and prognosis among Japanese patients with nonvalvular AF (NVAF), a post hoc analysis was conducted using observational data in the J-RHYTHM Registry. Subjects were categorized as underweight (BMI <18.5), normal (18.5 to 24.9), overweight (25.0 to 29.9), or obese (≥30 kg/m(2)). End points included thromboembolism, major hemorrhaging, all-cause mortality, and cardiovascular mortality. Of the 7,406 patients with NVAF, 6,379 patients (70 ± 10 years old; BMI, 23.6 ± 3.9 kg/m(2)) having baseline BMI data constituted the study group. During the 2-year follow-up period, 111 patients had thromboembolism, 124 experienced major hemorrhage, and 159 died. Multivariate analysis with the Cox proportional hazards model showed that none of the BMI categories were independent predictors of thromboembolism. However, being underweight was an independent predictor of all-cause mortality (hazard ratio [HR] 2.45; 95% confidence interval [CI] 1.62 to 3.69; p <0.001) and cardiovascular mortality (HR 3.00, 95% CI 1.52 to 5.91, p = 0.001) when normal weight was used as the reference. Additionally, being overweight was a predictor of lower all-cause mortality (HR 0.60, 95% CI 0.37 to 0.95, p = 0.029). In conclusion, being underweight is associated with higher risks of all-cause and cardiovascular mortality compared with having a normal weight. Being overweight or obese is not associated with increased mortality among Japanese patients with NVAF.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27255662     DOI: 10.1016/j.amjcard.2016.04.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review.

Authors:  Jeffrey I Mechanick; Michael E Farkouh; Jonathan D Newman; W Timothy Garvey
Journal:  J Am Coll Cardiol       Date:  2020-02-11       Impact factor: 24.094

Review 2.  Gender Differences in Arrhythmias: Focused on Atrial Fibrillation.

Authors:  Xiao-Ting Tian; Ying-Jia Xu; Yi-Qing Yang
Journal:  J Cardiovasc Transl Res       Date:  2019-10-21       Impact factor: 4.132

3.  Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China atrial fibrillation registry study.

Authors:  Lu Wang; Xin Du; Jian-Zeng Dong; Wen-Na Liu; Ying-Chun Zhou; Song-Nan Li; Xue-Yuan Guo; Chen-Xi Jiang; Rong-Hui Yu; Cai-Hua Sang; Ri-Bo Tang; De-Yong Long; Nian Liu; Rong Bai; Laurent Macle; Chang-Sheng Ma
Journal:  Clin Res Cardiol       Date:  2019-04-05       Impact factor: 5.460

Review 4.  The impact of underweight and obesity on outcomes in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis on the obesity paradox.

Authors:  Maxim Grymonprez; Andreas Capiau; Tine L De Backer; Stephane Steurbaut; Koen Boussery; Lies Lahousse
Journal:  Clin Cardiol       Date:  2021-03-26       Impact factor: 2.882

5.  The Characteristics and Clinical Outcomes of Direct Oral Anticoagulantsin Patients with Atrial Fibrillation and Chronic Kidney Disease: From the Database of A Single-Center Registry.

Authors:  Takao Sato; Yoshifusa Aizawa; Hitoshi Kitazawa; Masaaki Okabe
Journal:  J Atr Fibrillation       Date:  2020-08-31

Review 6.  Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review.

Authors:  Wengen Zhu; Rong Wan; Fuwei Liu; Jinzhu Hu; Lin Huang; Juxiang Li; Kui Hong
Journal:  J Am Heart Assoc       Date:  2016-09-09       Impact factor: 5.501

7.  Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.

Authors:  Yuji Murakawa; Takanori Ikeda; Satoshi Ogawa; Takanari Kitazono; Jyoji Nakagawara; Kazuo Minematsu; Susumu Miyamoto; Yasuhiro Hayashi; Yoko Kidani; Yutaka Okayama; Toshiyuki Sunaya; Shoichiro Sato; Satoshi Yamanaka
Journal:  Heart Vessels       Date:  2020-04-06       Impact factor: 2.037

8.  Gender-specific association between body mass index and all-cause mortality in patients with atrial fibrillation.

Authors:  Si-Qi Lyu; Yan-Min Yang; Jun Zhu; Juan Wang; Shuang Wu; Han Zhang; Xing-Hui Shao; Jia-Meng Ren
Journal:  Clin Cardiol       Date:  2020-04-30       Impact factor: 2.882

9.  Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hiroshi Inoue; Hirotsugu Atarashi; Hirofumi Tomita; Ken Okumura; Takeshi Yamashita; Hideki Origasa
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-10

10.  Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry.

Authors:  Vicente Bertomeu-Gonzalez; José Moreno-Arribas; María Asunción Esteve-Pastor; Inmaculada Roldán-Rabadán; Javier Muñiz; Paula Raña-Míguez; Martín Ruiz-Ortiz; Ángel Cequier; Vicente Bertomeu-Martínez; Lina Badimón; Manuel Anguita; Gregory Y H Lip; Francisco Marín
Journal:  J Am Heart Assoc       Date:  2019-12-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.